Work

Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx373.045

Authors: M. Payton, D. Pinchasik, A. Mehta, S. Goel, J.M. Zain, L. Sokol, E. Jacobsen, M.R. Patel, S.M. Horwitz, F. Meric-Bernstam, A. Shustov, D. Weinstock, M. Aivado, D.A. Annis

Institutions: Aileron (United States), University of Alabama at Birmingham, Montefiore Medical Center, City Of Hope National Medical Center, City of Hope, Moffitt Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon, Florida Cancer Specialists & Research Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Seattle Cancer Care Alliance

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761941968

FWCI: 0.607

Cites:

Cited by: 8

Related to: 10